denosumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
denosumab: clinical details
Prescribing considerations
- Confirm the licensed indication and corresponding formulation.
- Correct hypocalcaemia and assess calcium and vitamin D intake before initiation.
- Assess oral health and jaw-necrosis risk; consider preventive dentistry when risk factors are present.
- Plan continuity or an appropriate transition before stopping osteoporosis treatment because rebound bone loss and multiple vertebral fractures may occur.
- The osteoporosis formulation should not be used in people younger than 18 years; oncology use in adolescents is restricted to skeletally mature patients with the licensed tumour indication.
- Record the brand and batch number for biological-product traceability.
Contraindications and cautions
- Both selected products: hypersensitivity to denosumab or an excipient.
- Obodence: hypocalcaemia.
- Osenvelt: severe untreated hypocalcaemia and unhealed lesions following dental or oral surgery.
Monitoring
- Check calcium before treatment and whenever symptoms suggest hypocalcaemia.
- For the osteoporosis formulation, check calcium before each administration and after initial treatment in patients predisposed to hypocalcaemia.
- For the oncology formulation, check calcium before initial administration, within two weeks afterwards and more often when risk factors are present.
- Increase vigilance in severe renal impairment or dialysis; no renal dose adjustment is specified, but hypocalcaemia risk rises substantially.
- Monitor oral symptoms, new thigh or groin pain and persistent ear symptoms.
- After stopping treatment for giant cell tumour of bone, monitor for symptomatic rebound hypercalcaemia and reassess supplementation.
Clinical pharmacology
Denosumab is a recombinant human IgG2 monoclonal antibody targeting RANKL. Blocking RANK signalling suppresses osteoclast development, function and survival, reducing cortical and trabecular bone resorption.
Formulation and product differences
- Obodence is a single-use pre-filled syringe licensed for adult osteoporosis and specified causes of bone loss; an appropriately trained person may administer it.
- Osenvelt is a single-use vial licensed for skeletal complications of advanced malignancy and selected giant cell tumours of bone; a healthcare professional must administer it.
- Both require refrigerated, light-protected storage and must not be frozen or shaken, but their excipients and permitted room-temperature storage conditions differ.
denosumab preparations and strengths
Injection
Route: Parenteral
Strengths: 60 mg, 60 mg/mL, 120 mg
denosumab interactions
Duplicate bone-resorption treatment and medicines that increase hypocalcaemia or jaw-necrosis risk require attention.
Other denosumab-containing products
Do not use concurrently because this duplicates the same active treatment.
Bisphosphonates
The cancer and giant-cell-tumour formulation should not be given concurrently with a bisphosphonate.
Systemic corticosteroids
They may add to hypocalcaemia and osteonecrosis-of-the-jaw risk, so stronger risk assessment and monitoring may be needed.
Sources
These sources were used to prepare and review this medicine page.
iatroX CPD
Keep a note for CPD
Save a private reflection with this source attached. Your first is free.
Record learning (opens in a new tab)Prepared and reviewed by the iatroX editorial team.